Surrozen (SRZN) to Release Earnings on Wednesday

Surrozen (NASDAQ:SRZN) is expected to be announcing its earnings results before the market opens on Wednesday, April 9th. Analysts expect the company to announce earnings of ($2.54) per share for the quarter.

Surrozen (NASDAQ:SRZN) last released its quarterly earnings results on Monday, March 31st. The company reported ($9.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.54) by ($6.56). The business had revenue of $0.66 million for the quarter. On average, analysts expect Surrozen to post $-8 EPS for the current fiscal year and $-11 EPS for the next fiscal year.

Surrozen Stock Down 4.6 %

Shares of SRZN opened at $11.12 on Wednesday. The firm’s fifty day simple moving average is $11.33 and its two-hundred day simple moving average is $11.02. Surrozen has a 12 month low of $6.00 and a 12 month high of $18.17.

Insider Transactions at Surrozen

In other news, major shareholder Group Gp Lp Column III acquired 1,034,482 shares of the firm’s stock in a transaction dated Wednesday, March 26th. The stock was purchased at an average price of $11.60 per share, for a total transaction of $11,999,991.20. Following the completion of the acquisition, the insider now directly owns 795,411 shares in the company, valued at $9,226,767.60. The trade was a -432.71 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 43.50% of the company’s stock.

Wall Street Analysts Forecast Growth

SRZN has been the subject of several recent analyst reports. HC Wainwright assumed coverage on Surrozen in a research note on Thursday, January 30th. They set a “buy” rating and a $32.00 target price for the company. Guggenheim upgraded shares of Surrozen from a “neutral” rating to a “buy” rating and set a $45.00 price objective for the company in a research note on Friday, January 3rd.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.